A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. ##STR00001##

Compositions, devices and methods of using one or more hydrogel for contraception as well as localized, sustained delivery of drugs are disclosed. Device (e.g., hydrogel) embodiments are easily injectable, have a quick gelation rate, are highly durable, and are capable of lasting greater than 3 months in vivo. The devices/hydrogel may be used for occlusion of a bodily duct, such as the vas deferens and/or fallopian tubes, for male and female contraception, respectively. Once implanted, the device/hydrogel is able to release one or more drugs, such as small molecules or biologics, indirectly, systemically, and/or directly to the site of interest over a sustained period of time, such as for prevention and/or treatment of STIs.

Compositions, devices and methods of using one or more hydrogel for contraception as well as localized, sustained delivery of drugs are disclosed. Device (e.g., hydrogel) embodiments are easily injectable, have a quick gelation rate, are highly durable, and are capable of lasting greater than 3 months in vivo. The devices/hydrogel may be used for occlusion of a bodily duct, such as the vas deferens and/or fallopian tubes, for male and female contraception, respectively. Once implanted, the device/hydrogel is able to release one or more drugs, such as small molecules or biologics, indirectly, systemically, and/or directly to the site of interest over a sustained period of time, such as for prevention and/or treatment of STIs.

Drug Delivery Silicone Composition to improve Active ingredient Elution. The invention relates to a new curable liquid silicone rubber composition which after curing provides a silicone elastomer useful as a drug delivery device comprising an active pharmaceutical ingredient (API) having terminal alkene, alkyne or carbonyl functionalities exhibiting an increased recovery of the active pharmaceutical ingredient.

The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive.

A composition includes a contraceptive chimeric virus-like particle with an antigenic carrier domain and one or more antigenic regions from a sperm cell in the antigenic carrier domain, with the antigenic carrier domain including human papillomavirus L1 capsid protein and the antigenic regions including one or more structural elements of the Catsper ion channel complex. When administered to a patient, the contraceptive vaccine stimulates production of anti-sperm antibodies that, upon binding to a sperm cell, inhibit the sperm cell's motility and thus inhibit the ability of the sperm cell to fertilize an egg cell. The induced immunoinfertility of the composition can be reversed for brief or extended lengths of time by overdosing the patient with a reversal agent lacking the antigenic carrier domain but having a protein sequence substantially identical to that of the one or more antigenic regions to sequester the anti-sperm antibodies.

Isolated antibodies, antigen-binding portions or fragments thereof or antibody-drug conjugates which bind specifically to a propeptide region of human SAS1B, such as amino acids 34-53 and/or amino acids 64-86 of human SAS1B, are disclosed. Therapeutic and diagnostic applications and methods of use, such as for cancer therapeutics, contraception and fertility, are also disclosed.

A delivery device for active pharmaceutical agents and made up of a hollow polymeric outer shape forming at least one closed internal cavity or compartment and containing a solid core of one or more active pharmaceutical agents and one or more excipients substantially unattached to the hollow polymeric outer shape is provided. Also provided are methods for production and use of this device.

Described are methods of providing contraception in a woman having a BMI≥30.0 kg/m.sup.2, comprising: selecting a woman determined to have a BMI≥30.0 kg/m.sup.2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also described are methods of contraception that achieves a Pearl Index of <5 in women having a BMI≥30.0 kg/m.sup.2, comprising: selecting a woman determined to have a BMI≥30.0 kg/m.sup.2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg, wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.